Observational Study to Evaluate PAD Treatment Clinical and Economic Outcomes (LIBERTY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01855412

Recruitment Status : Active, not recruiting

First Posted : May 16, 2013

Last Update Posted : June 21, 2018

Sponsor:

Information provided by (Responsible Party):

Cardiovascular Systems Inc

Study Description

Brief Summary:

The purpose of this study is to evaluate acute and long term clinical and economic outcomes of endovascular procedures to treat Peripheral Arterial Disease (PAD).

Condition or disease	Intervention/treatment
Peripheral Arterial Occlusive Disease	Other: PAD endovascular treatments

Detailed Description:

This is a prospective, observational, multi-center, clinical study examining predictors of clinical outcomes for patients undergoing endovascular treatment of lesions within or extending into the target area (10 cm above the medial epicondyle to the digital arteries). This includes disease in a vessel located within or extending into the distal superficial femoral artery (SFA), popliteal (POP), tibial peroneal trunk (TPT), anterior tibial (AT), posterior tibial (PT), and peroneal tibial (PR) arteries.

Study Design


Study Type :	Observational
Actual Enrollment :	1204 participants
Observational Model:	Cohort
Time Perspective:	Prospective
Official Title:	LIBERTY 360: Prospective, Observational, Multi-Center Clinical Study to Evaluate Acute and Long Term Clinical and Economic Outcomes of Endovascular Device Intervention in Patients With Distal Outflow Peripheral Arterial Disease (PAD)
Study Start Date :	May 2013
Estimated Primary Completion Date :	December 2020
Estimated Study Completion Date :	December 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Peripheral Arterial Disease

U.S. FDA Resources

Groups and Cohorts

Group/Cohort	Intervention/treatment
Claudication (Rutherford 2-3) Patients who have been diagnosed with PAD and are classified as on the Rutherford Scale as Rutherford 2-3. Patients may be treated with any FDA-cleared endovascular PAD treatment.	Other: PAD endovascular treatments All FDA-cleared endovascular PAD treatments
CLI Rutherford 4-5 Patients who have been diagnosed with PAD and classified on the Rutherford Scale as Rutherford 4-5. Patients may be treated with any FDA-cleared endovascular PAD treatment.	Other: PAD endovascular treatments All FDA-cleared endovascular PAD treatments
CLI Rutherford 6 Patients who have been diagnosed with PAD and classified on the Rutherford Scale as Rutherford 6. Patients may be treated with any FDA-cleared endovascular PAD treatment.	Other: PAD endovascular treatments All FDA-cleared endovascular PAD treatments

Outcome Measures

Primary Outcome Measures :

Procedural success of Endovascular PAD Treatment(s) [ Time Frame: After the last subject's 5-year follow-up visit ]
Final post-procedural result of < 50% residual stenosis for all treated lesions during index procedure and without angiographic complications as determined by the Angiographic Core Laboratory.

Secondary Outcome Measures :

Lesion Success of Endovascular PAD Treatment(s) [ Time Frame: After the last subject's 5-year follow-up visit ]
Final post-procedural result of < 50% residual stenosis for a given lesion treated during index procedure without angiographic complications as determined by the Angiographic Core Laboratory.

Other Outcome Measures:

Rate of Major Adverse Events (MAEs) [ Time Frame: After the last subject's 5-year follow-up visit ]
The rate of the following MAEs as reported by the Investigators will be assessed during the subject's participation in the study:
- Death within 30 days of index procedure
- Unplanned major (above the ankle) amputation of the target limb
- Clinically-driven TLR (Target Lesion Revascularization) and/or TVR (Target Vessel Revascularization) of the target limb

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Patients who have been determined by their physician to require endovascular device treatment for their PAD.

Criteria

Inclusion Criteria:

Subject's age ≥ 18 years.
Subject presents with a Rutherford classification of 2 to 6.
Subject presents with clinical evidence of PAD requiring endovascular intervention on one or both limbs that includes a target lesion in a native vessel located within or extending into 10 cm above the medial epicondyle to the digital arteries.
- If subject presents with bilateral disease, the first limb treated with a lesion in the target area will be considered the target limb.
- For subjects with one or more wounds on the target limb, the target lesion(s) should be considered the lesion(s) in the vessel(s) that provide(s) blood flow to the wound(s).
Subject has at least one lesion in a native vessel located within or extending into the target area that is crossed and treated with an endovascular device.

Exclusion Criteria:

Subject is unwilling or unable to sign the IRB-approved informed consent form (ICF).
Subject is unable to understand or comply with the study protocol requirements.
Subject is currently participating in an investigational drug or other device study that can clinically interfere with the endpoints of this study.
Subject requires a conversion from endovascular intervention to a surgical bypass graft for any lesion(s) in the target area, as determined by the Investigator.
Subject has an in-stent restenosis in the target area, and this lesion is the only one requiring treatment.
Subject is pregnant or planning to become pregnant within the study period.
Subject has an anticipated life span of less than one (1) year.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01855412

Show 53 Study Locations

Sponsors and Collaborators

Cardiovascular Systems Inc

Investigators


Principal Investigator:	William Gray, MD	Columbia University
Principal Investigator:	Gary Ansel, MD	Riverside Methodist Hospital
Principal Investigator:	George Adams, MD	Rex Healthcare
Principal Investigator:	Jihad Mustapha, MD	Advanced Cardiac & Vascular Centers

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Adams GL, Mustapha J, Gray W, Hargus NJ, Martinsen BJ, Ansel G, Jaff MR. The LIBERTY study: Design of a prospective, observational, multicenter trial to evaluate the acute and long-term clinical and economic outcomes of real-world endovascular device interventions in treating peripheral artery disease. Am Heart J. 2016 Apr;174:14-21. doi: 10.1016/j.ahj.2015.12.013. Epub 2015 Dec 30.


Responsible Party:	Cardiovascular Systems Inc
ClinicalTrials.gov Identifier:	NCT01855412 History of Changes
Other Study ID Numbers:	CLN-0001-P
First Posted:	May 16, 2013 Key Record Dates
Last Update Posted:	June 21, 2018
Last Verified:	June 2018

Keywords provided by Cardiovascular Systems Inc:


PAD LIBERTY Observational

Additional relevant MeSH terms:


Peripheral Arterial Disease Arterial Occlusive Diseases Atherosclerosis Arteriosclerosis	Vascular Diseases Cardiovascular Diseases Peripheral Vascular Diseases

To Top